Ny-Eso-1 Olp4 Vaccine With Poly-Iclc
Unresectable or Metastatic Melanoma
Ludwig Institute for Cancer ResearchvaccinePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
104 Active assets in the Unresectable or Metastatic Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib M.D. Anderson Cancer Center | Phase 2 | BBB |
DACARBAZINE Shanghai Junshi Bioscience Co., Ltd. | Phase 4 | BBB |
Ifa Craig L Slingluff, Jr | Phase 2 | BB |
Nivolumab Bristol-Myers Squibb | Phase 4 | BB |
Montanide Isa 51 Ludwig Institute for Cancer Research | Phase 2 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →